In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viatris GmbH

Division of Mylan NV
www.viatris.com

Latest From Viatris GmbH

SciClone Takes Deeper Plunge In China Following Solid Q1 Results

SciClone sees more opportunities ahead as it plans deeper expansion into China, following Q1 results that posted a 38% increase in sales for its lead product.

China Emerging Markets

Validating Europe's De-Risked Approach

Novartis' deal on COPD compound AD 237, co-developed by Vectura and Arakis, proves that low-risk "re-profilers" can win big bucks. But the program must be right, and so must the partner's portfolio. It isn't about the technology-it's about the product.
BioPharmaceutical Europe

German Biotech: Coalescing around the Haves

Positive signs are coming out of German biotech for the first time in years. Scientific output remains strong. The subsector boasts its first profitable pharmaceutical-oriented company; several on- or near-market products, and even a nascent IPO market. The fact that dozens of companies are expected to go bust this year is another sign of the industry's maturation. The long-awaited consolidation predicted in the wake of the Neuer Markt demise is seemingly finally happening. The have-nots are finally beginning to cluster around the haves.
BioPharmaceutical Strategy

Strakan/Proskelia: Creating Long-Term Value

Symphony attempted to re-create an off-P&L financing vehicle for biotech projects that would both pass the much tougher SEC scrutiny applied since the late 1990s and allow biotechs to avoid licensing away what could be important revenue generators. To do so, it had to create a fully independent corporate vehicle with the capacity-through an alliance with an equity-incentivized CRO--to manage its own development. But its first biotech partner, Guilford Pharmaceuticals, didn't feel Symphony had proven the financing could be completely off-P&L. Consolidating the expenses, Guilford sees the deal's value largely in the additional management resources, along with the funding, that Symphony provides a second-priority program. Symphony also has yet to prove it can make its investors money from these projects: in part because the value of late-stage programs has increased since the original off-P&L vehicles were created, Symphony could only get from Guilford a single compound, not a portfolio of projects with which to reduce its investment risk.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Asta Medica AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Mylan NV
  • Senior Management
  • Markus Peterseim, CEO
    Paul Taaffe, CFO
    Harald Borbe, CSO
    Dirk Groen, SVP, Strategic Mktg. & Bus. Dev.
  • Contact Info
  • Viatris GmbH
    Phone: (49) 69 4001 2812
    Weismullerstrasse 45
    P.O. Box 100105 Frankfurt am Main, D-60314
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register